Bionomics Limited is pleased to announce that it has initiated its Phase 2 clinical trial (the PREVAIL Study) to evaluate BNC210 for the acute treatment of Social Anxiety Disorder (SAD), with topline results expected by the end of 2022. BNC210 is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor in development for the acute treatment of the SAD and chronic treatment of Post-Traumatic Stress Disorder (PTSD) with the U.S. FDA Fast Track designation for both clinical indications.

Source: Bionomics Limited

Social anxiety disorder (SAD) is characterized by persistent anxiety when exposed to observation or scrutiny by others and fear of acting in a way that will be embarrassing or humiliating. SAD is divided into generalized and non-generalized subtypes. In the former, most social situations are feared. In the latter, either a single or several social or performance situations are feared. The impact of social anxiety is widespread, affecting functioning in various domains of life and lowering general mood and wellbeing.

• A lifetime prevalence of SAD of up to 12% has been reported in the U.S., and 12-month prevalence rates of .8% have been reported across Europe and 0.2% in China.

However, the current Social anxiety disorder (SAD) treatment market share, market uptake, attribute analysis concerning the most potential emerging therapies (PH94B, BHV-0223, GW876008, BNC210, atomoxetine, VQW-765, etc.) have been provided under the market outlook section of the study covering 8 MM countries; The United States, EU5 (Germany, Spain, France, Italy, UK) Japan and China.

In terms of pharmacologic therapies, several pharmaceutical products are being approved and under different phases of development for Social anxiety disorder (SAD) treatment. The key companies in the advanced development stage are VistaGen Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., GlaxoSmithKline, Bionomics Limited, Eli Lilly and Company, etc.

Based on solid domain and business knowledge, Thelansis Knowledge Partners has published the market outlook report on Social anxiety disorder (SAD) to provide a clear understanding of disease area background, epidemiology, current and future competitions, the country-specific standard of care, and the complete market forecast for 2020 to 2030.

Thelansis specializes in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area, including rare / ultra-rare and mainstream indication. Over the period, we have built a robust repository of 6,000+ Bio-pharma reports that cover Epidemiology studies and Market forecasting based on the KOL opinions.

Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the primary focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.

• Delivery Office:
  B-1030, C Wing Vrindavan tech village, Outer ring road
  Bangalore- 560037
  India+91(124)404-1731
  clientsupport@thelansis.com
• Sales office:
  183 Asylum Street Hartford,
  CT-06103, USA
  Contact no. +1 (302) 380-3552
  m.berg@thelansis.com